STTK
Shattuck Labs, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Neutral
+10/100
Last price
5.86
▼ 0.64 (9.85%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
6.30
Prev close
6.50
Day high
6.65
Day low
5.85
Volume
1.60M
Market cap
$588.13M
P/E (TTM)
—
52W range
1.70 – 8.33
Day trading desk
Gap from prior close
-3.08%
Prior close 6.50
VWAP
6.05
-3.14% from price
Relative volume
1.21×
Normal
Session range
13.68%
5.85 – 6.65
Position in range
1%
Near session low
ATR (14D)
0.50
8.47% of price
Prior day high
6.85
PDH
Prior day low
6.30
PDL
Bid / ask spread
—
Quote not published
Session volume
1.45M
Avg 1.19M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-10.40%
-12.3%
1M
-13.70%
-14.9%
3M
-14.83%
-19.3%
6M
-13.57%
-31.8%
YTD
+60.55%
+46.3%
1Y
+149.36%
+132.9%
3Y
+285.53%
+203.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on STTK open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+15.85M
Net buying
Buy transactions
15
15.94M shares
Sell transactions
5
85.91K shares
Net transactions
+20
Buys less sells
Sell : buy shares
0.0 : 1
Mixed
Insider-held shares
4.09M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jul 6, 26 | SHUKLA ABHINAV A. PH.D. Chief Technology Officer |
CONVERSION | 12.56K | $44.85K | Direct |
| Jul 2, 26 | SHUKLA ABHINAV A. PH.D. Chief Technology Officer |
SELL | 410 | $2.87K | Direct |
| Jul 1, 26 | SHUKLA ABHINAV A. PH.D. Chief Technology Officer |
SELL | 23.46K | $166.13K | Direct |
| Jul 1, 26 | SHUKLA ABHINAV A. PH.D. Chief Technology Officer |
CONVERSION | 23.46K | $83.77K | Direct |
| Jun 30, 26 | PANDITE ARUNDATHY N. Officer |
SELL | 30.00K | $210.30K | Direct |
| Jun 9, 26 | SIEGALL CLAY B Director |
BUY | 62.50K | $250.00K | Direct |
| Jun 8, 26 | ASHIYA MONA Director |
CONVERSION | 15.37M | $59.93M | Indirect |
| May 22, 26 | SIEGALL CLAY B Director |
STOCK | 128.05K | $781.13K | Direct |
| May 22, 26 | SIEGALL CLAY B Director |
CONVERSION | 128.05K | $781.13K | Direct |
| May 21, 26 | SHUKLA ABHINAV A. PH.D. Chief Technology Officer |
STOCK | 5.12K | $31.19K | Direct |
| May 21, 26 | SHUKLA ABHINAV A. PH.D. Chief Technology Officer |
CONVERSION | 5.12K | $31.19K | Direct |
| May 15, 26 | STOUT STEPHEN General Counsel |
STOCK | 12.80K | $80.16K | Direct |
| May 15, 26 | STOUT STEPHEN General Counsel |
CONVERSION | 12.80K | $80.16K | Direct |
| May 12, 26 | SHUKLA ABHINAV A. PH.D. Chief Technology Officer |
SELL | 2.03K | $14.24K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ASHIYA MONA |
Director | — | Conversion of Exercise of derivative security |
NEILL ANDREW R. |
Chief Financial Officer | 292.25K | Stock Award(Grant) |
ORBIMED ADVISORS, L.L.C. |
Unknown | — | Purchase |
PANDITE ARUNDATHY N. |
Officer | 136.22K | Sale |
REDMILE GROUP, L.L.C. |
Director and Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
SCHREIBER TAYLOR M.D., PH.D. |
Chief Executive Officer | 2.73M | Stock Award(Grant) |
SHUKLA ABHINAV A. PH.D. |
Chief Technology Officer | 98.53K | Conversion of Exercise of derivative security |
SIEGALL CLAY B |
Director | 318.61K | Purchase |
STOUT STEPHEN |
General Counsel | 93.37K | Stock Award(Grant) |
Fundamentals
Market cap$588.13M
Enterprise value$382.50M
Revenue (TTM)$1.00M
Gross profit$-38.24M
EBITDA$-52.14M
Net income$-52.57M
EPS (TTM)$-0.47
Free cash flow$-21.22M
Total cash$208.30M
Total debt$2.67M
Book value / share$2.10
Shares outstanding100.36M
Float67.76M
Short % of float7.03%
Dividend yield0.00%
Beta (5Y)1.10
Valuation & profitability ratios
Trailing P/E—
Forward P/E-11.02
PEG ratio—
Price / sales—
Price / book2.80
EV / revenue382.50
EV / EBITDA-7.34
Gross margin0.00%
Operating margin-5570.50%
Profit margin0.00%
Return on equity-39.21%
Return on assets-24.43%
Debt / equity1.27
Current ratio27.59
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $1.00M | $5.72M | $1.66M | $652.00K | -82.5% |
| Operating revenue | $1.00M | $5.72M | $1.66M | $652.00K | -82.5% |
| Research & development | $35.27M | $67.21M | $74.31M | $82.90M | -47.5% |
| Selling, general & admin | $17.23M | $19.08M | $19.30M | $21.08M | -9.7% |
| Total operating expense | $52.51M | $86.29M | $93.61M | $103.98M | -39.1% |
| Operating income | -$51.51M | -$80.57M | -$91.96M | -$103.33M | +36.1% |
| Net interest income | $2.70M | $5.17M | $4.67M | $1.59M | -47.8% |
| Pre-tax income | -$48.81M | -$75.41M | -$87.30M | -$101.94M | +35.3% |
| Net income | -$48.81M | -$75.41M | -$87.30M | -$101.94M | +35.3% |
| Net income to common | -$48.81M | -$75.41M | -$87.30M | -$101.94M | +35.3% |
| Basic EPS | -0.70 | -1.49 | -2.05 | -2.41 | +53.0% |
| Diluted EPS | -0.70 | -1.49 | -2.05 | -2.41 | +53.0% |
| EBIT | -$51.51M | -$80.57M | -$91.96M | -$103.33M | +36.1% |
| EBITDA | -$47.82M | -$76.74M | -$87.92M | -$100.26M | +37.7% |
| Basic shares | 69.58M | 50.76M | 42.60M | 42.38M | +37.1% |
| Diluted shares | 69.58M | 50.76M | 42.60M | 42.38M | +37.1% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $54.19M | $57.39M | $125.63M | $47.38M | -5.6% |
| Cash & short-term investments | $78.06M | $72.99M | $130.63M | $161.28M | +7.0% |
| Total current assets | $82.47M | $79.22M | $143.22M | $184.58M | +4.1% |
| Property, plant & equipment | $6.11M | $9.81M | $13.80M | $17.67M | -37.7% |
| Total assets | $91.03M | $91.05M | $159.56M | $205.32M | -0.0% |
| Total current liabilities | $7.05M | $8.92M | $11.45M | $24.96M | -20.9% |
| Total debt | $2.42M | $3.41M | $4.20M | $4.90M | -28.9% |
| Total liabilities | $8.64M | $11.42M | $14.86M | $29.17M | -24.4% |
| Retained earnings | -$430.53M | -$381.72M | -$306.31M | -$219.01M | -12.8% |
| Shareholder equity | $82.39M | $79.63M | $144.71M | $176.16M | +3.5% |
| Working capital | $75.42M | $70.30M | $131.77M | $159.62M | +7.3% |
| Net tangible assets | $82.39M | $79.63M | $144.71M | $176.16M | +3.5% |
| Shares issued | 63.28M | 47.71M | 47.26M | 42.39M | +32.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$48.81M | -$75.41M | -$87.30M | -$101.94M | +35.3% |
| Depreciation & amortisation | $3.69M | $3.83M | $4.04M | $3.07M | -3.7% |
| Stock-based compensation | $7.00M | $9.55M | $6.94M | $6.46M | -26.7% |
| Change in working capital | -$785.00K | $3.02M | -$4.09M | -$4.46M | -126.0% |
| Operating cash flow | -$39.88M | -$60.52M | -$81.23M | -$94.50M | +34.1% |
| Capital expenditure | -$71.00K | -$59.00K | -$407.00K | -$11.61M | -20.3% |
| Investing cash flow | -$7.89M | -$8.51M | $110.86M | $49.44M | +7.3% |
| Share buybacks | — | -$17.00K | — | — | — |
| Financing cash flow | $44.57M | $787.00K | $48.62M | $171.00K | +5,563.8% |
| Free cash flow | -$39.95M | -$60.57M | -$81.64M | -$106.11M | +34.0% |
| End cash position | $54.19M | $57.39M | $125.63M | $47.38M | -5.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $1.00M | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $1.00M | $0 | — | — |
| Research & development | $11.70M | $10.95M | $9.05M | $7.62M | $8.68M | — | +6.9% |
| Selling, general & admin | $4.46M | $4.60M | $4.32M | $4.10M | $4.35M | — | -3.1% |
| Total operating expense | $16.16M | $15.54M | $13.37M | $11.72M | $13.03M | — | +3.9% |
| Operating income | -$16.16M | -$15.54M | -$13.37M | -$10.72M | -$13.03M | — | -3.9% |
| Net interest income | $1.03M | $779.00K | — | — | $804.00K | $689.00K | +32.1% |
| Pre-tax income | -$15.15M | -$14.77M | -$12.59M | -$10.06M | -$12.46M | — | -2.6% |
| Net income | -$15.15M | -$14.77M | -$12.59M | -$10.06M | -$12.46M | — | -2.6% |
| Net income to common | -$15.15M | -$14.77M | -$12.59M | -$10.06M | -$12.46M | — | -2.6% |
| Basic EPS | -0.12 | -0.13 | -0.12 | -0.14 | -0.24 | — | +7.7% |
| Diluted EPS | -0.12 | -0.13 | -0.12 | -0.14 | -0.24 | — | +7.7% |
| EBIT | -$16.16M | -$15.54M | -$13.37M | -$10.72M | -$13.03M | — | -3.9% |
| EBITDA | -$15.30M | -$14.65M | -$12.46M | -$9.80M | -$12.10M | — | -4.4% |
| Basic shares | 129.78M | 112.23M | 103.78M | 72.18M | 51.00M | — | +15.6% |
| Diluted shares | 129.78M | 112.23M | 103.78M | 72.18M | 51.00M | — | +15.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $63.30M | $90.42M | $54.19M | $42.55M | $50.47M | -30.0% |
| Cash & short-term investments | $208.30M | $90.42M | $78.06M | $86.13M | $50.47M | +130.4% |
| Total current assets | $213.27M | $93.75M | $82.47M | $90.72M | $54.67M | +127.5% |
| Property, plant & equipment | $4.51M | $5.35M | $6.11M | $7.05M | $7.95M | -15.7% |
| Total assets | $220.67M | $102.12M | $91.03M | $100.33M | $64.37M | +116.1% |
| Total current liabilities | $7.73M | $4.25M | $7.05M | $5.34M | $5.34M | +81.9% |
| Total debt | $2.67M | $2.89M | $2.42M | $2.63M | $2.97M | -7.4% |
| Total liabilities | $9.53M | $6.29M | $8.64M | $7.09M | $7.35M | +51.6% |
| Retained earnings | -$460.45M | -$445.30M | -$430.53M | -$417.94M | -$407.88M | -3.4% |
| Shareholder equity | $211.14M | $95.83M | $82.39M | $93.24M | $57.02M | +120.3% |
| Working capital | $205.54M | $89.50M | $75.42M | $85.39M | $49.34M | +129.6% |
| Net tangible assets | $211.14M | $95.83M | $82.39M | $93.24M | $57.02M | +120.3% |
| Shares issued | 100.73M | 75.58M | 63.28M | 63.15M | 47.90M | +33.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$15.15M | -$14.77M | -$12.59M | -$10.06M | -$12.46M | -2.6% |
| Depreciation & amortisation | $851.00K | $891.00K | $906.00K | $917.00K | $929.00K | -4.5% |
| Stock-based compensation | $2.73M | $2.42M | $1.61M | $1.78M | $1.89M | +13.2% |
| Change in working capital | $2.13M | -$2.05M | $1.71M | -$477.00K | -$916.00K | +203.9% |
| Operating cash flow | -$10.19M | -$13.42M | -$8.49M | -$8.93M | -$10.43M | +24.1% |
| Investing cash flow | -$144.95M | $23.85M | $20.00M | -$43.49M | $0 | -707.8% |
| Financing cash flow | $128.01M | $25.80M | $134.00K | $44.50M | $0 | +396.1% |
| Free cash flow | -$10.33M | -$13.42M | -$8.49M | -$9.00M | -$10.43M | +23.1% |
| End cash position | $63.30M | $90.42M | $54.19M | $42.55M | $50.47M | -30.0% |
Options analytics
Put / call volume
0.02
Call-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
6.00
+2.4% from spot
ATM implied vol
6.3%
Nearest strike to spot
Skew (10% OTM)
-6.2%
Calls bid over puts
Call volume
51
Contracts, this expiry
Put volume
1
Contracts, this expiry
Heaviest call OI
6.00
0 contracts
Heaviest put OI
6.00
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.12 | -0.12 | +2.8% |
| Mar 2026 | -0.13 | -0.13 | +1.5% |
| Dec 2025 | -0.13 | -0.12 | +11.0% |
| Sep 2025 | -0.15 | -0.14 | +4.1% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.11 | 10 | $37.50K | -96.3% |
| Next quarter | -0.12 | 10 | $88.89K | 0.0% |
| Current year | -0.48 | 10 | $111.11K | -88.9% |
| Next year | -0.53 | 10 | $111.11K | 0.0% |
Analyst targets & ownership
Mean target$15.22
High target$19.00
Low target$10.00
Implied upside159.76%
Analyst count9
ConsensusSTRONG BUY
Strong buy / Buy3 / 8
Hold0
Sell / Strong sell0 / 0
Held by insiders4.08%
Held by institutions80.08%
Institutions holding141
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
6.45
-9.09% from price
SMA 20
6.28
-6.73% from price
SMA 50
6.88
-14.81% from price
SMA 100
6.44
-8.99% from price
SMA 200
5.88
-0.26% from price
EMA 12
6.41
-8.62% from price
EMA 26
6.52
-10.09% from price
EMA 50
6.62
-11.44% from price
RSI (14)
37.8
Neutral
MACD (12,26,9)
-0.10
Hist 0.03
ATR (14)
0.50
8.47% of price
Realised vol 30D
55.4%
Annualised
Bollinger upper
6.88
20, 2σ
Bollinger lower
5.68
20, 2σ
50 / 200 cross
Golden
6.88 vs 5.88
Trend bias
Below 200
-0.26%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.30
More volatile than market
Correlation to SPY
0.21
Largely independent
Realised vol 30D
55.4%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-50.5%
Peak to trough
Max drawdown 5Y
-96.4%
Peak to trough
ATR 14
0.50
8.47% of price
Beta (reported)
1.10
5Y monthly, from filing
Short interest
Shares short
6.81M
Prior 6.01M
Change vs prior
+13.4%
Shorts adding
% of float
7.03%
Normal
% of shares out
6.78%
Against total outstanding
Days to cover
8.7
Crowded exit
Float
67.76M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 2, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| Oct 2, 26 | Needham | MAINTAINED | Buy | Buy |
| Aug 24, 26 | Raymond James | INITIATED | — | Strong Buy |
| Aug 11, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jul 24, 26 | JP Morgan | INITIATED | — | Overweight |
| Jul 20, 26 | Leerink Partners | INITIATED | — | Outperform |
| Jun 9, 26 | Citigroup | MAINTAINED | Buy | Buy |
| Jun 8, 26 | Needham | MAINTAINED | Buy | Buy |
| Jun 8, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jun 5, 26 | Citigroup | UPGRADE | Neutral | Buy |
| May 8, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| Apr 27, 26 | Cantor Fitzgerald | INITIATED | — | Overweight |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Periodic Financial Reports
10-Q · 2026-08-11
Corporate Changes & Voting Matters
8-K · 2026-06-09
Corporate Changes & Voting Matters
8-K · 2026-06-02
Periodic Financial Reports
10-Q · 2026-05-07
Proxy Statements
DEF 14A · 2026-04-08
Corporate Changes & Voting Matters
8-K · 2026-03-05
Corporate Changes & Voting Matters
8-K · 2026-02-05
Corporate Changes & Voting Matters
8-K · 2026-01-22
Headlines
Update: Wedbush Lifts Price Target on Shattuck Labs to $14 From $11, Keeps Outperform Rating
MT Newswires · 6d ago
Wedbush Lifts Price Target on Shattuck Labs to $14 From $11, Keeps Outperform Rating
MT Newswires · 6d ago
Shattuck Labs Plans Phase 2 Trial of Chronic Inflammatory Skin Disease Drug
MT Newswires · 6d ago
Shattuck Labs Announces Phase 2 Clinical Trial of SL-325 in Hidradenitis Suppurativa and Appointment of Shoba Ravichandran, M.D., as Senior Vice President, Clinical Development
GlobeNewswire · 6d ago
Hut 8 Insider Sold Shares Worth $2,000,000, According to a Recent SEC Filing
MT Newswires · 8d ago
Shattuck Labs Announces Participation in Upcoming September Investor Conferences
GlobeNewswire · 34d ago
What Shattuck Labs Stock Topped the Market on Monday
Motley Fool · 43d ago
Raymond James Initiates Coverage on Shattuck Labs With Strong Buy Rating, $18 Price Target
MT Newswires · 44d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.